Lutzomyia longipalpis polypeptides and methods of use

Details Lutzomyia longipalpis polypeptides and methods of use Lutzomyia longipalpis polypeptides and methods of use

2003-10-29

2009-02-03

Mondesi, Robert B (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S184100, C424S185100, C530S300000, C530S350000, C435S069400, C435S069700, C536S023100, C536S023700

Reexamination Certificate

active

07485306

ABSTRACT:
Substantially purified salivaryLu. longipalpispolypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including theLu. longipalpispolynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.

REFERENCES:
patent: WO 95/06729 (1995-03-01), None
patent: WO 02/102324 (2002-12-01), None
patent: WO 2004/027041 (2004-04-01), None
Soares et al , An. Acad. Bras. Ciēnc. vol. 75 No. 3 Rio de Janeiro Sep. 2003.
Brodie et al (Infection and Immunity 2007, 75; 2359-2365).
Milleron et al teach (Am. J. Trop. Med. Hyg., 70(3), 2004, pp. 286-293).
Bowie et al. Science, vol. 247: 1990; p. 1306; p. 1308.
Charlab et al 1999 Proc Natl Acad Sci U S A. Dec. 21, 1999; 96(26): 15155-60.
Sousa et al Mem. Inst. Oswaldo Cruz vol. 96, No. 7 Rio de Janeiro Oct. 2001.
Gomes et al., “Seroconversion againstLutzomiya longipalpisSaliva Concurrent with the Development of Anti-Leishmania chagasiDelayed-Type Hypersensitivity,”Journal of Infectious Diseases, 186(10):1530-1534, 2002.
Valenzuela et al., “Identification of the most abundant secreted proteins from the salivary glands of the sand flyLutzomyia longipalpis, vector ofLeishmania chagasi,”The Journal of Experimental Biology, 207(21):3717-3729, 2004.
Adler et al., “The mouthparts, alimentary tract and salivary apparatus of the femalePhlebotomus papatasi,” Ann. Trop. Med. Parasitol. 20:109, 1926.
Barral et al., “Human immune response to sand fly salivary gland antigens: a useful epidemiological marker?”Am. J. Trop. Med. Hyg. 62:740-745, 2000.
Belkaid et al., “A natural model ofLeishmania majorinfection reveals a prolonged “silent” phase of parasite amplification in the skin before the onset of lesion formation and immunity,”J. Immunol. 165:969-977, 2000
Belkaid et al., “Delayed-type hypersensitivity toPhlebotomus papatasisand fly bite: an adaptive response induced by the fly?”Proc. Natl. Acad. Sci. USA97:6704-6709, 2000.
Belkaid et al., “Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome ofLeishmania majorinfection in the mouse ear dermis,”J. Exp. Med. 188:1941-1953, 1998.
Charlab et al., “Toward an understanding of the biochemical and pharmacological complexity of the saliva of a hematophagous sand fly Lutzomyia longipalpis,”Proc. Natl. Acad. Sci., USA. 96(26):15155-15160, 1999.
Haskó et al., “Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice,”J. Immunol., 157(10):4634-4640, 1996.
Haskó et al., “Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms,”FASEB J., 14(13):2065-2074, 2000.
Gurunathan et al., “Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected withLeishmania major,” J. Exp. Med. 186:1137-1147, 1997.
Gurunathan et al., “Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection,”Nat. Med. 4:1409-1415, 1998.
Kamhawi et al., “Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies,”Science290:1351-1354, 2000.
Katz et al., “Adenosine, AMP, and protein phosphatase activity in sand fly saliva,”Am. J. Trop. Med. Hyg. 62:145-150, 2000.
Killick-Kendrick, Biology ofLeishmaniain phlebotomine sand flies. In Biology of the Kinetoplastida. W. Lumsden and D. Evans, editors. Academic Press, New York. 395, 1979.
Lerner et al., “Isolation of maxadilan, a potent vasodilatory peptide from the salivary glands of the sand fly Lutzomyia longipalpis,”J. Biol. Chem., 266(17):11234-11236, 1991.
Makoul et al., “Prostaglandin E2 inhibits the activation of cloned T cell hybridomas,”J. Immunol., 134(4):2645-2650, 1985.
Mellanby, “Man's Reaction to Mosquito Bites,”Nature158(4016):554-555, 1946.
Méndez et al., “The potency and durability of DNA- and protein-based vaccines againstLeishmania majorevaluated using low dose, intradermal challenge,”J. Immunol. 166(8):5122-5128, 2001.
Modi et al., “A simple technique for mass rearingLutzomyia longipalpisandPhlebotomus papatasi(Diptera: Psychodidae) in the laboratory,”J. Med. Ent. 20:568-569, 1983.
Nong et al., “Peptides encoded by the calcitonin gene inhibit macrophage function,”J. Immunol., 143(1):45-49, 1989.
Qureshi et al., “Immunomodulatory properties of maxadilan, the vasodilator peptide from sand fly salivary gland extracts,”Am. J. Trop. Med. Hyg., 54(6):665-671, 1996.
Ribeiro et al., “Blood-finding strategy of a capillary-feeding sandfly, Lutzomyia longipalpis,”Comp. Biochem. Physiol., 83(4):683-686, 1986.
Ribeiro et al., “Salivary apyrase activity of some Old World phlebotomine sand flies,”Insect Biochem. 19:409-412, 1989.
Ribeiro et al., “Salivary glands of the sand fly Phlebotomus papatasi contain pharmacologically active amounts of adenosine and 5′-AMP,”J. Exp. Biol., 202(Pt. 11):1551-1559, 1999.
Santoli et al., “Prostaglandin E precursor fatty acids inhibit human IL-2 production by a prostaglandin E-independent mechanism,” and Zurier,J. Immunol., 143(4):1303-1309, 1989.
Sjölander et al., “Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis,”J. Immunol. 160:3949-3957, 1998.
Smelt et al., “B cell-deficient mice are highly resistant toLeishmania donovaniinfection, but develop neutrophil-mediated tissue pathology,”J. Immunol. 164:3681-3688, 2000.
Soares et al., “The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-alpha and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor,”J. Immunol. 160:1811-1816, 1998.
Stockman et al., “The effect of prostaglandins on the in vitro blastogenic response of human peripheral blood lymphocytes,”Exp. Hematol., 2(2):65-72, 1974.
Theodos et al., “Analysis of enhancing effect of sand fly saliva onLeishmaniainfection in mice,”Infect. Immun. 59:1592-1598, 1991.
Titus et al., “Salivary gland lysates from the sand flyLutzomyia longipalpisenhancedLeishmaniainfectivity,”Science239:1306-1308, 1988.
Titus et al., “The role of vector saliva in transmission of arthropod-borne disease,”Parasitology Today6(5):157-160, 1990.
Valenzuela et al., “The salivary apyrase of the blood-sucking sand fly Phlebotomus papatasi belongs to the novel Cimex family of apyrases,”J. Experimental Biology, 204:229-237, 2001.
Valenzuela et al., “Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein,”J. Exp. Med. 194(3):331-342, 2001.
Webster, “Role of purines in lymphocyte function,”Asian Pac. J. Allergy Immunol., 2(2):311-317, 1984.
Xu et al., “Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, ofL. major,” Immunology84:173-176, 1995.
Database A—Genseq—Jun. 29, 2004 Accession No. ABB71995, Mar. 26, 2002, 1 page.
Database A—Genseq—Jun. 29, 2004 Accession No. ABG18028, Feb. 18, 2002, 1 page.
Database SPTrEMBL Accession No. Q95WD8, Dec. 19, 2001, 6 pages.
Database SPTrEMBL Accession No. Q23404, Jun. 6, 1998, 5 pages.
Database A—Genseq—Jun. 29, 2004 Accession No. AAG03191, Oct. 6, 2000, 1 page.
Database A—Genseq—Jun. 29, 2004 Accession No. ABG24332, Feb. 18, 2002, 1 page.

Affiliated with

Also associated with

Rating

Lutzomyia longipalpis polypeptides and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lutzomyia longipalpis polypeptides and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lutzomyia longipalpis polypeptides and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4138503